AGIOS PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $90.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $90.05M.
- AGIOS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$104.09M, a 224.41% decline from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $83.67M, a 40.58% increase from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $59.52M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $90.05M 10-K · filed 2026-02-12 | |
| 2024-12-31 | -$104.09M 10-K · filed 2026-02-12 | |
| 2023-12-31 | $83.67M 10-K · filed 2025-02-13 | |
| 2022-12-31 | $59.52M 10-K · filed 2024-02-15 | |
| 2021-12-31 | -$358.27M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $92.54M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $111.46M 10-K · filed 2021-02-25 | $111.40M 10-K · filed 2020-02-19 |
| 2018-12-31 | $88.80M 10-K · filed 2019-02-14 | |
| 2017-12-31 | $88.80M 10-K · filed 2020-02-19 | $93.90M 10-K · filed 2018-02-14 |
| 2016-12-31 | $86.10M 10-K · filed 2018-02-14 | |
| 2015-12-31 | $52.50M 10-K · filed 2018-02-14 | |
| 2014-12-31 | $22.90M 10-K · filed 2015-02-24 | |
| 2013-12-31 | $14.80M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |